---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-122456"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2025-05-19T23:59:59+00:00"
generated_at: "2026-05-21T01:37:21.593211+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO closes up to $250M royalty bond with HCRx; $150M funded, cash runway into early 2027

## Summary
- Received $150M at closing; up to $250M total via three tranches, including $50M contingent on Zolgensma sales threshold by Apr 2027.
- Royalty bond bears interest at 9.75% + 3-month SOFR (4.25% floor); repayment solely from royalties on Zolgensma, RGX-121, RGX-111, and NAV platform licensees.
- Issued HCRx warrant for 268,096 shares at $14.92 (100% premium to 30-day VWAP), exercisable for 10 years.
- Extends expected cash runway into early 2027, funding late-stage programs including RGX-121, RGX-202, and ABBV-RGX-314.
- Retains future non-dilutive sources: potential Priority Review Voucher for RGX-121 and milestones from AbbVie and Nippon Shinyaku.

## SEC filing metadata
- accession: 0001193125-25-122456
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2025-05-19T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000119312525122456/0001193125-25-122456-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000119312525122456/d31892d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-122456
- JSON: https://secwatch.observer/filing/0001193125-25-122456.json
- Plain text: https://secwatch.observer/filing/0001193125-25-122456.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.